NO20034345D0 - Pyridazinon aldose reduktase inhibitorer - Google Patents

Pyridazinon aldose reduktase inhibitorer

Info

Publication number: NO20034345D0
Authority: NO; Norway
Prior art keywords: reductase inhibitors; aldose reductase; pyridazinone aldose; pyridazinone; inhibitors
Prior art date: 2001-03-30

Application number

NO20034345A

Other languages

English (en)

Norwegian (no)

Other versions

NO20034345L (no

Inventor

Banavara Lakshman Mylari

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2003-09-29

Publication date

2003-09-29

2003-09-29 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-09-29 Publication of NO20034345D0 publication Critical patent/NO20034345D0/no

2003-09-29 Publication of NO20034345L publication Critical patent/NO20034345L/no

Links

AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
239000003288 aldose reductase inhibitor Substances 0.000 title 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20034345A 2001-03-30 2003-09-29 Pyridazinon aldose reduktase inhibitorer NO20034345L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28005101P	2001-03-30	2001-03-30
PCT/IB2002/000320 WO2002079198A1 (fr)	2001-03-30	2002-01-31	Inhibiteurs pyridazinone d'aldose réductase

Publications (2)

Publication Number	Publication Date
NO20034345D0 true NO20034345D0 (no)	2003-09-29
NO20034345L NO20034345L (no)	2003-09-29

Family

ID=23071435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20034345A NO20034345L (no)	2001-03-30	2003-09-29	Pyridazinon aldose reduktase inhibitorer

Country Status (43)

Country	Link
US (2)	US6579879B2 (fr)
EP (3)	EP1491541B1 (fr)
JP (1)	JP2004528319A (fr)
KR (1)	KR100586138B1 (fr)
CN (1)	CN1215067C (fr)
AP (1)	AP2002002461A0 (fr)
AR (1)	AR035798A1 (fr)
AT (3)	ATE348100T1 (fr)
AU (1)	AU2002226634B2 (fr)
BG (1)	BG108179A (fr)
BR (1)	BR0208571A (fr)
CA (1)	CA2442476A1 (fr)
CZ (1)	CZ20032563A3 (fr)
DE (3)	DE60217930T2 (fr)
DK (2)	DK1491540T3 (fr)
EA (1)	EA006023B1 (fr)
EC (1)	ECSP034671A (fr)
EE (1)	EE200300470A (fr)
ES (2)	ES2274369T3 (fr)
GE (1)	GEP20053675B (fr)
HR (1)	HRP20030752A2 (fr)
HU (1)	HUP0303644A3 (fr)
IL (1)	IL156462A0 (fr)
IS (3)	IS2205B (fr)
MA (1)	MA27003A1 (fr)
MX (1)	MXPA03008850A (fr)
MY (1)	MY134304A (fr)
NO (1)	NO20034345L (fr)
NZ (1)	NZ528406A (fr)
OA (1)	OA12453A (fr)
PA (1)	PA8541801A1 (fr)
PE (1)	PE20030007A1 (fr)
PL (1)	PL365294A1 (fr)
PT (2)	PT1373259E (fr)
SI (1)	SI1373259T1 (fr)
SK (1)	SK11852003A3 (fr)
TN (1)	TNSN02037A1 (fr)
TW (1)	TWI245762B (fr)
UA (1)	UA73236C2 (fr)
UY (1)	UY27237A1 (fr)
WO (1)	WO2002079198A1 (fr)
YU (1)	YU71403A (fr)
ZA (1)	ZA200304671B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL189872B1 (pl)	1996-07-24	2005-10-31	Warner Lambert Co	Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
ATE297902T1 (de) *	2001-02-28	2005-07-15	Pfizer Prod Inc	Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
EP1491541B1 (fr) *	2001-03-30	2007-01-24	Pfizer Products Inc.	Pyridazinones, inhibiteurs d'aldose reductase.
AU761191B2 (en) *	2001-05-24	2003-05-29	Pfizer Products Inc.	Therapies for tissue damage resulting from ischemia
IL162594A0 (en) *	2002-01-09	2005-11-20	Pfizer Prod Inc	Process and intermediates for pyridazinone antidiabetic agents
US7419981B2 (en) *	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) *	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US6872833B2 (en) *	2003-04-14	2005-03-29	Hoffmann-La Roche Inc.	Adenosine receptor ligands
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (fr) *	2004-06-30	2006-03-16	Whitehead Institute For Biomedical Research	Procedes pour analyse de site haut rendement au niveau du genome
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7645752B2 (en) *	2006-01-13	2010-01-12	Wyeth Llc	Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
RS53230B (sr)	2006-06-27	2014-08-29	Takeda Pharmaceutical Company Limited	Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US8173645B2 (en) *	2007-03-21	2012-05-08	Takeda San Diego, Inc.	Glucokinase activators
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
ES2758554T3 (es)	2009-12-08	2020-05-05	Univ Case Western Reserve	Aminoácidos gama para tratamiento de trastornos oculares
US8916563B2 (en)	2010-07-16	2014-12-23	The Trustees Of Columbia University In The City Of New York	Aldose reductase inhibitors and uses thereof
US9296692B2 (en) *	2011-09-15	2016-03-29	Taipei Medical University	Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
US9339542B2 (en) *	2013-04-16	2016-05-17	John L Couvaras	Hypertension reducing composition
EP2986599A1 (fr)	2013-04-17	2016-02-24	Pfizer Inc.	Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
CN103739547B (zh) *	2014-01-03	2015-09-02	沈阳药科大学	2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
AU2016248080A1 (en) *	2015-04-14	2017-11-02	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (fr)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	Nouvelles formes pharmaceutiques du sildénafil
RS61239B1 (sr)	2016-06-21	2021-01-29	Univ Columbia	Inhibitori aldozne reduktaze i postupci korišćenja
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
EP3548035A4 (fr)	2016-11-30	2020-07-22	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
IL272246B2 (en)	2017-07-28	2026-01-01	Applied Therapeutics Inc	History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
KR102921276B1 (ko)	2018-11-21	2026-02-03	케이스 웨스턴 리저브 유니버시티	단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
BR112021013807A2 (pt)	2019-01-18	2021-11-30	Astrazeneca Ab	Inibidores de pcsk9 e seus métodos de uso
CA3132136A1 (fr)	2019-04-01	2020-10-08	Andrew Wasmuth	Inhibiteurs de l'aldose reductase
JP2022531466A (ja)	2019-05-07	2022-07-06	ユニバーシティオブマイアミ	遺伝性ニューロパチーおよび関連障害の処置および検出
CA3142351A1 (fr)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
CA3141826A1 (fr)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations
WO2022120353A1 (fr) *	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE47592B1 (en)	1977-12-29	1984-05-02	Ici Ltd	Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en)	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
US4996204A (en)	1989-05-11	1991-02-26	Pfizer Inc.	Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (fr) *	1990-11-30	1992-06-11	Tsumura & Co.	Derive de benzopyrone et inhibiteur de reductase d'aldose contenant ce derive en tant qu'ingredient actif
WO1992017446A2 (fr)	1991-03-28	1992-10-15	Pfizer Inc.	Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase
US5834466A (en)	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1017691A1 (fr) *	1997-09-24	2000-07-12	Orion Corporation (Orion-Yhtyma Oy)	Bisethers de 1-oxa, aza et thianaphtalene-2-one inhibiteurs du phospholambane
FR2822827B1 (fr) *	2001-03-28	2003-05-16	Sanofi Synthelabo	Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1491541B1 (fr) *	2001-03-30	2007-01-24	Pfizer Products Inc.	Pyridazinones, inhibiteurs d'aldose reductase.
CA2445871A1 (fr) *	2001-04-30	2002-11-07	Pfizer Products Inc.	Combinaisons d'inhibiteurs d'aldose reductase et inhibiteurs de cyclo-oxygenase 2
IL162594A0 (en) *	2002-01-09	2005-11-20	Pfizer Prod Inc	Process and intermediates for pyridazinone antidiabetic agents

2002
- 2002-01-31 EP EP04023150A patent/EP1491541B1/fr not_active Expired - Lifetime
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/fr not_active Expired - Lifetime
- 2002-01-31 EP EP02716247A patent/EP1373259B1/fr not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active Expired - Fee Related
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/fr not_active Abandoned
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/fr not_active Ceased
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown

Also Published As

Publication number	Publication date
EP1491540B1 (fr)	2006-12-13
DE60202452T2 (de)	2006-02-09
OA12453A (en)	2006-05-24
CN1500087A (zh)	2004-05-26
PT1491540E (pt)	2007-01-31
IS6845A (is)	2003-06-16
WO2002079198A1 (fr)	2002-10-10
YU71403A (sh)	2006-05-25
DE60202452D1 (de)	2005-02-03
US20020143017A1 (en)	2002-10-03
AR035798A1 (es)	2004-07-14
EP1491541A1 (fr)	2004-12-29
PA8541801A1 (es)	2002-10-28
US6849629B2 (en)	2005-02-01
GEP20053675B (en)	2005-11-25
EE200300470A (et)	2004-02-16
EA006023B1 (ru)	2005-08-25
PE20030007A1 (es)	2003-01-28
ATE286049T1 (de)	2005-01-15
ES2231681T3 (es)	2005-05-16
ZA200304671B (en)	2004-06-25
DK1373259T3 (da)	2005-03-29
BG108179A (en)	2004-09-30
CZ20032563A3 (cs)	2004-05-12
DE60216823D1 (de)	2007-01-25
IS2205B (is)	2007-02-15
UA73236C2 (en)	2005-06-15
TWI245762B (en)	2005-12-21
KR20030088484A (ko)	2003-11-19
IS8251A (is)	2006-01-23
ATE348100T1 (de)	2007-01-15
CN1215067C (zh)	2005-08-17
HK1061678A1 (en)	2004-09-30
ES2274369T3 (es)	2007-05-16
MY134304A (en)	2007-12-31
AP2002002461A0 (en)	2002-06-30
TNSN02037A1 (fr)	2005-12-23
PT1373259E (pt)	2005-03-31
IS8250A (is)	2006-01-23
EA200300673A1 (ru)	2003-12-25
HUP0303644A2 (hu)	2004-03-01
MA27003A1 (fr)	2004-12-20
AU2002226634B2 (en)	2007-01-25
EP1373259A1 (fr)	2004-01-02
NZ528406A (en)	2004-03-26
ATE352551T1 (de)	2007-02-15
SI1373259T1 (en)	2005-04-30
EP1491541B1 (fr)	2007-01-24
US20030162784A1 (en)	2003-08-28
UY27237A1 (es)	2002-12-31
DE60216823T2 (de)	2007-10-04
JP2004528319A (ja)	2004-09-16
HUP0303644A3 (en)	2008-06-30
PL365294A1 (en)	2004-12-27
ECSP034671A (es)	2003-08-29
DE60217930D1 (de)	2007-03-15
US6579879B2 (en)	2003-06-17
CA2442476A1 (fr)	2002-10-10
MXPA03008850A (es)	2003-12-04
EP1491540A1 (fr)	2004-12-29
DE60202452C5 (de)	2006-11-23
BR0208571A (pt)	2004-03-23
KR100586138B1 (ko)	2006-06-07
HRP20030752A2 (en)	2005-06-30
EP1373259B1 (fr)	2004-12-29
NO20034345L (no)	2003-09-29
DE60217930T2 (de)	2007-10-18
IL156462A0 (en)	2004-01-04
SK11852003A3 (sk)	2004-07-07
DK1491540T3 (da)	2007-03-26

Publication	Publication Date	Title
ATE352551T1 (de)	2007-02-15	Pyridazinon aldose reductase inhibitoren
CY2015028I1 (el)	2016-07-27	Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60234125D1 (de)	2009-12-03	E inhibitoren
ATE397925T1 (de)	2008-07-15	Cis-imidazoline als mdm2-hemmer
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
DE60218138D1 (de)	2007-03-29	Rho-kinase inhibitoren
DE60301683D1 (de)	2005-11-03	Leseverstärker
ATE368651T1 (de)	2007-08-15	Pyridazinon-derivate als gsk-3beta-hemmer
IS7243A (is)	2004-04-30	C-5 breytt indazólýlpýrrólótríazín
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE333454T1 (de)	2006-08-15	Metalloproteinaseinhibitoren
EE200300439A (et)	2003-12-15	Metalloproteinaasi inhibiitorid
NO20042742L (no)	2004-08-24	Pyrimidinforbindelser
DE60239456D1 (de)	2011-04-28	Amplifizierungsverfahren
DE60201856D1 (de)	2004-12-16	Klasse-D Verstärker
EP1570847A4 (fr)	2008-10-08	Inhibiteurs de phosphodiesterase 10a
EP1434436A4 (fr)	2007-12-12	Lecteur
DE60222443D1 (de)	2007-10-25	Vorverstärkungsschaltung
SE0100694D0 (sv)	2001-02-28	DHFR inhibitors
ITVA20020070A1 (it)	2004-06-18	Composizioni farmaceutico-dietetiche comprendenti inibitori della hmg-coa reduttasi e/o polielettroliti.
ATE270267T1 (de)	2004-07-15	Scyphostatin-analoga als smase-inhibitoren
UA5096S (uk)	2001-08-15	Суцільнометалевий піввагон
FI20010995L (fi)	2002-11-12	Audiovahvistin
FI20011758A0 (fi)	2001-09-05	Henkilökohtainen virtsauslaite